EUCTR2004-002601-69-IT进行中（未招募）不适用
A phase II study to determine the activity of BMS-354825 in subjects with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia who have disease that is resistant to high dose imatinib mesylate (Gleevec) or who are intolerant of imatinib
BRISTOL-M.SQUIBB0 个研究点目标入组 240 人开始时间: 2005年4月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with ChronicPhase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who HaveDisease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who areIntolerant of ImatinibRevised Protocol 01 version 4.0, incorporating Amendment 02 and Administrative Letter dated 01-Mar-2005, and Amendment 01 version 2.0 dated 28-Apr-2005Chronic phase Philadelphia chromosome-positive chronic myeloid leukemiaEUCTR2004-002601-69-DKBristol Myers Squibb International Corporation250
进行中（未招募）
不适用
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with ChronicPhase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who HaveDisease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who areIntolerant of ImatinibRevised Protocol 01 version 4.0, incorporating Amendment 02 and Administrative Letter dated 01-Mar-2005, and Amendment 01 version 2.0 dated 28-Apr-2005EUCTR2004-002601-69-DEBristol Myers Squibb International Corporation250
进行中（未招募）
不适用
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with ChronicPhase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who HaveDisease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who areIntolerant of ImatinibChronic phase Philadelphia chromosome-positive chronic myeloid leukemiaEUCTR2004-002601-69-ATBristol Myers Squibb International Corporation250
进行中（未招募）
1 期
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with ChronicPhase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who HaveDisease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who areIntolerant of ImatinibRevised Protocol 01 version 4.0, incorporating Amendment 02 and Administrative Letter dated 01-Mar-2005, and Amendment 01 version 2.0 dated 28-Apr-2005Chronic phase Philadelphia chromosome-positive chronic myeloid leukemiaEUCTR2004-002601-69-GBBristol Myers Squibb International Corporation250
进行中（未招募）
不适用
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with ChronicPhase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who HaveDisease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who areIntolerant of ImatinibRevised Protocol 01 version 4.0, incorporating Amendment 02 and Administrative Letter dated 01-Mar-2005, and Amendment 01 version 2.0 dated 28-Apr-2005Chronic phase Philadelphia chromosome-positive chronic myeloid leukemiaEUCTR2004-002601-69-BEBristol Myers Squibb International Corporation250